Avelas Biosciences is a biotechnology company focused on developing pegloprastide (also known as AVB-620) with the goal of revolutionizing cancer surgery with real-time margin detection. In a pivotal trial in women with early-stage breast cancer undergoing a lumpectomy, intraoperative imaging of pegloprastide detected up to 75% of the positive margins that resulted from standard-of-care techniques. Beyond breast cancer, pegloprastide has the potential to significantly improve outcomes in a variety of other cancer surgeries.
Apr 29, 2021
Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast SurgeonsRead more
Dec 14, 2020
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer SurgeryRead more
Aug 04, 2020
Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer SurgeryRead more